The Intelligence Platform for Emerging Therapeutics
Evidence. Transparency. Regulatory Clarity.
Evterra delivers trusted intelligence on peptides, GLP-1 therapies, longevity compounds, metabolic health technologies, and emerging therapeutics — through evidence analysis, scientific summaries, community intelligence, and real-time regulatory monitoring.
Educational Intelligence Platform • Evidence-Based Insights • Not Medical Advice
Healthcare Intelligence Is Fragmented
Consumers, clinicians, and researchers face an overwhelming volume of scientific studies, regulatory developments, pricing changes, therapeutic claims, and rapidly evolving healthcare information — with no centralized platform to organize it.
Information Overload
Thousands of new studies, claims, and discussions appear weekly. Signal disappears into noise.
Regulatory Complexity
Updates scatter across the FDA, PCAC, state boards, and academic publications with no single view.
Lack of Trusted Intelligence
Community information is inconsistent. There is no neutral, evidence-graded source of truth.
Meet Evterra
Evterra brings scientific evidence, regulatory developments, community intelligence, therapeutic insights, physician discussion tools, and real-world outcomes into a single sophisticated intelligence platform — transforming fragmented information into understandable intelligence.
Evterra Intelligence Engine
Synthesizes, grades, and contextualizes every signal.
A complete intelligence stack
Six tightly integrated modules built for evidence-driven decisions.
Compound Intelligence Library
Comprehensive profiles: mechanisms of action, evidence grading, safety, regulatory status, references, pricing intelligence, and clinical insights.
Regulatory Watch
Track FDA developments, PCAC meetings, enforcement actions, legal-access changes, alerts, and policy developments in real time.
Compare Therapies
Side-by-side comparison of compounds, therapies, evidence quality, safety profiles, costs, satisfaction ratings, and outcomes.
Community Intelligence
Structured ratings, real-world user experiences, discontinuation reasons, satisfaction scores, side-effect reporting, biomarker trends, and goal-achievement insights — aggregated anonymously to surface what actually works.
My Protocol
Securely track compounds, biomarkers, symptoms, side effects, outcomes, and therapeutic journeys over time to better understand personal results.
Doctor Discussion Reports
Generate physician-ready summaries that organize protocols, biomarkers, outcomes, side effects, and evidence references to support informed healthcare conversations.
Evterra Intelligence Engine
Transforming fragmented healthcare information into trusted therapeutic intelligence.
What outcomes actually look like in the real world
A preview of Evterra's structured therapeutic intelligence network — transforming individual experiences into actionable, anonymized healthcare insights while preserving user privacy.
BPC-157
Tirzepatide
MOTS-C
Illustrative examples of platform capability. Evterra is building a structured therapeutic intelligence network that transforms individual experiences into actionable healthcare insights — while maintaining user privacy through anonymized, aggregated reporting.
The Moment Is Now
Therapeutic innovation, regulatory complexity, and consumer demand are converging — fast.
- 2023GLP-1 therapies enter mainstream demand
- 2024Longevity & peptide science expands rapidly
- 2024FDA & PCAC intensify regulatory scrutiny
- 2025Mitochondrial & regenerative therapeutics emerge
- 2026Consumers demand trustworthy intelligence
YoY GLP-1 prescription growth
Peptide-related publications in 2025
FDA & PCAC actions tracked annually
A Massive Intelligence Opportunity
Hundreds of billions in global opportunity across categories shaping the next decade of medicine.
Over time, Evterra's greatest asset may become its proprietary therapeutic intelligence network — capturing anonymized trends in outcomes, satisfaction, discontinuation reasons, safety observations, and physician discussion activity across emerging therapeutic categories.
Healthcare consumerization is rewriting the demand curve.
Patients, employers, and investors all need a single trusted lens on emerging therapeutics. Evterra is being built to be that lens.
Founded by Gary D. Alexander, JD, EdD
National Healthcare Leader, Reformer, Regulator, and Policy Expert
Gary D. Alexander is a nationally recognized healthcare executive, public policy leader, healthcare reform expert, educator, and organizational transformation leader with more than two decades of experience transforming health and human services systems.
He has served as Secretary of Health and Human Services and Medicaid Director for both Rhode Island and Pennsylvania, leading some of the most significant healthcare transformation initiatives in the United States.
Throughout his career, he has overseen multi-billion-dollar healthcare programs, Medicaid systems, regulatory oversight, program integrity efforts, and large-scale government operations — generating billions in taxpayer savings while improving access, accountability, and quality outcomes.
Join the Founding Community
Be among the first to access Evterra and help shape the future of healthcare intelligence. Founding members get early access, priority onboarding, and a direct line to our team.
- Priority access to the Compound Intelligence Library
- Private regulatory briefings
- Direct input on roadmap and features
Built on Trust and Transparency
Always consult qualified healthcare professionals before making healthcare decisions.
Building the Future of Therapeutic Intelligence
Evterra is being built to become the trusted intelligence layer connecting evidence, regulation, therapeutic innovation, and real-world insights across emerging healthcare technologies. As therapeutic innovation accelerates, the need for trusted intelligence becomes increasingly important.